MCSG: A Method for Simultaneous Disproportionality Analysis and Background Rate Estimation in Large Pharmacovigilance Databases

Drug Safety · Published 2025-12-06 · DOI 10.1007/s40264-025-01632-8

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s40264-025-01632-8

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• Perspective on Better Access to Data and Data Integration in Pharmacovigilance: Information from a Focus Group · Drug Safety · 2026 · Same journal
• A Large Language Model for Extracting Post-marketing Adverse Drug Events from Clinical Notes in the Electronic Health Record · Drug Safety · 2026 · Same journal
• Pharmacovigilance Through Fresh Eyes: The International Society of Pharmacovigilance Student Community's Role in Shaping the Future of Pharmacovigilance · Drug Safety · 2026 · Same journal
• Reliability of Self-Reported Maternal Health and Mother–Infant Outcome Data in Web-Based Questionnaires · Drug Safety · 2026 · Same journal
• Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant · Drug Safety · 2026 · Same journal
• Pharmacovigilance Due Diligence in Drug Development: A Practical Playbook for Risk Identification, Compliance Assessment, and Strategic Decision Making · Drug Safety · 2025 · Same journal
• US Risk Evaluation and Mitigation Strategies with Elements to Assure Safe Use: A Longitudinal Analysis of REMS Modifications (2008–2022) · Drug Safety · 2026 · Same journal
• GP Consultations for Herpes Zoster After COVID-19 Vaccination: A Self-Controlled Cohort Study Based on Electronic Health Record Data from the Netherlands · Drug Safety · 2025 · Same journal
• Health Information Exchanges (HIEs) as Novel Sources for Population-Based Post Marketing Surveillance of Medical Products: A Pilot Study from the FDA Sentinel Innovation Center · Drug Safety · 2026 · Same journal
• Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus · Drug Safety · 2025 · Same journal